Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
398 studies found for:    "Chronic myelomonocytic leukemia"
Show Display Options
Rank Status Study
1 Completed Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
2 Active, not recruiting Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
3 Completed
Has Results
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
4 Active, not recruiting Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Revlimid
5 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
6 Recruiting Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: lenzilumab
7 Recruiting Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Condition: Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Tipifarnib
8 Completed Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: Imatinib
9 Terminated Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Conditions: Acute Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: DTGM
10 Completed Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Conditions: Cancer;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
11 Active, not recruiting Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic
Intervention: Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
12 Completed Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myelogenous Leukemia (AML)
Interventions: Drug: Subcutaneous (SC) Azacitidine;   Drug: Oral Azacitidine
13 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
14 Active, not recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
15 Completed Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Azacitidine;   Drug: Volasertib
16 Not yet recruiting Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Conditions: Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions: Drug: Atezolizumab;   Drug: Guadecitabine
17 Completed A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myeloid Leukemia (AML)
Intervention: Drug: Panobinostat
18 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate
19 Completed Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
Condition: Leukemia
Interventions: Drug: azacitidine;   Other: laboratory biomarker analysis
20 Completed Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions: Drug: Azacitidine;   Drug: Erythropoetin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.